Literature DB >> 25267682

Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Natacha Coen1, Sophie Duraffour1, Dimitri Topalis1, Robert Snoeck1, Graciela Andrei2.   

Abstract

The susceptibilities of gammaherpesviruses, including Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), and animal rhadinoviruses, to various nucleoside analogs was investigated in this work. Besides examining the antiviral activities and modes of action of antivirals currently marketed for the treatment of alpha- and/or betaherpesvirus infections (including acyclovir, ganciclovir, penciclovir, foscarnet, and brivudin), we also investigated the structure-activity relationship of various 5-substituted uridine and cytidine molecules. The antiviral efficacy of nucleoside derivatives bearing substitutions at the 5 position was decreased if the bromovinyl was replaced by chlorovinyl. 1-β-D-Arabinofuranosyl-(E)-5-(2-bromovinyl)uracil (BVaraU), a nucleoside with an arabinose configuration of the sugar ring, exhibited no inhibitory effect against rhadinoviruses but was active against EBV. On the other hand, the fluoroarabinose cytidine analog 2'-fluoro-5-iodo-aracytosine (FIAC) showed high selectivity indices against gammaherpesviruses that were comparable to those of brivudin. Additionally, we selected brivudin- and acyclovir-resistant rhadinoviruses in vitro and characterized them by phenotypic and genotypic (i.e., sequencing of the viral thymidine kinase, protein kinase, and DNA polymerase) analysis. Here, we reveal key amino acids in these enzymes that play an important role in substrate recognition. Our data on drug susceptibility profiles of the different animal gammaherpesvirus mutants highlighted cross-resistance patterns and indicated that pyrimidine nucleoside derivatives are phosphorylated by the viral thymidine kinase and purine nucleosides are preferentially activated by the gammaherpesvirus protein kinase.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25267682      PMCID: PMC4249563          DOI: 10.1128/AAC.03957-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir.

Authors:  E A Gustafson; R F Schinazi; J D Fingeroth
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  The enhanced DNA replication fidelity of a mutant herpes simplex virus type 1 DNA polymerase is mediated by an improved nucleotide selectivity and reduced mismatch extension ability.

Authors:  Wang Tian; Ying T Hwang; Charles B C Hwang
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

3.  Inhibitory effect of cycloSaligenyl-nucleoside monophosphates (cycloSal-NMP) of acyclic nucleoside analogues on HSV-1 and EBV.

Authors:  A Meerbach; R Klöcking; C Meier; A Lomp; B Helbig; P Wutzler
Journal:  Antiviral Res       Date:  2000-01       Impact factor: 5.970

4.  Anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl] x guanine (A-5021) in vitro and in vivo.

Authors:  J Neyts; L Naesens; C Ying; L De Bolle; E De Clercq
Journal:  Antiviral Res       Date:  2001-02       Impact factor: 5.970

Review 5.  Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.

Authors:  E De Clercq; L Naesens; L De Bolle; D Schols; Y Zhang; J Neyts
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

6.  The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Authors:  Qiao Meng; Stacy R Hagemeier; Joyce D Fingeroth; Edward Gershburg; Joseph S Pagano; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

7.  Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase.

Authors:  Matthew J Lock; Nicola Thorley; Jeanette Teo; Vincent C Emery
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 8.  Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.

Authors:  Sunwen Chou
Journal:  Rev Med Virol       Date:  2008 Jul-Aug       Impact factor: 6.989

9.  Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Authors:  Fu-Zhang Wang; Debasmita Roy; Edward Gershburg; Christopher B Whitehurst; Dirk P Dittmer; Joseph S Pagano
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

10.  Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases.

Authors:  Natacha Coen; Sophie Duraffour; Kazuhiro Haraguchi; Jan Balzarini; Joost J van den Oord; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

View more
  10 in total

1.  Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines.

Authors:  Carrie B Coleman; Eric M Wohlford; Nicholas A Smith; Christine A King; Julie A Ritchie; Paul C Baresel; Hiroshi Kimura; Rosemary Rochford
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

Review 2.  The lytic phase of Epstein-Barr virus plays an important role in tumorigenesis.

Authors:  Yue Liang; Yan Zhang; Bing Luo
Journal:  Virus Genes       Date:  2022-10-15       Impact factor: 2.198

3.  Epstein-Barr Virus-Encoded BILF1 Orthologues From Porcine Lymphotropic Herpesviruses Display Common Molecular Functionality.

Authors:  Maša Mavri; Valentina Kubale; Daniel P Depledge; Jianmin Zuo; Christene A Huang; Judith Breuer; Milka Vrecl; Michael A Jarvis; Eva Jarc Jovičić; Toni Petan; Bernhard Ehlers; Mette M Rosenkilde; Katja Spiess
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

4.  Kaposi Sarcoma Herpesvirus Induces HO-1 during De Novo Infection of Endothelial Cells via Viral miRNA-Dependent and -Independent Mechanisms.

Authors:  Sara Botto; Jennifer E Totonchy; Jean K Gustin; Ashlee V Moses
Journal:  MBio       Date:  2015-06-04       Impact factor: 7.867

5.  Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus.

Authors:  Ondřej Baszczyňski; Martin Maxmilian Kaiser; Michal Česnek; Petra Břehová; Petr Jansa; Eliška Procházková; Martin Dračínský; Robert Snoeck; Graciela Andrei; Zlatko Janeba
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

Review 6.  Emerging small-molecule treatments for multiple sclerosis: focus on B cells.

Authors:  Aaron Gregson; Kaitlyn Thompson; Stella E Tsirka; David L Selwood
Journal:  F1000Res       Date:  2019-03-01

Review 7.  Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.

Authors:  Marc-Antoine Valantin; Léna Royston; Maxime Hentzien; Aude Jary; Alain Makinson; Marianne Veyri; Sylvie Ronot-Bregigeon; Stéphane Isnard; Romain Palich; Jean-Pierre Routy
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

8.  An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness.

Authors:  Erika Trompet; Arturo Temblador; Sarah Gillemot; Dimitrios Topalis; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

Review 9.  Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.

Authors:  D Topalis; S Gillemot; R Snoeck; G Andrei
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

Review 10.  Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.

Authors:  Eleonora Naimo; Jasmin Zischke; Thomas F Schulz
Journal:  Viruses       Date:  2021-09-09       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.